Victory Capital Management
CYCN icon

Victory Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

Victory Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-376
Closed -$20K – 2704
2020
Q1 		$20K Buy
+376
New +$26.8K ﹤0.01% 3091
2019
Q4 		– Sell
-131
Closed -$32K – 2797
2019
Q3 		$32K Buy
+131
New +$28.3K ﹤0.01% 2879

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management's CYCN Position: Q2 2020 in Review

Victory Capital Management sold out of Cyclerion Therapeutics (CYCN) in Q2 2020, closing a stake of 376 shares — an estimated $20K sold.

Victory Capital Management first reported a position in CYCN in Q3 2019 and held it in 2 quarters. The position peaked at $32K in Q3 2019. 74 funds tracked by Wall St. Rank hold CYCN as of Q2 2020.

  • Victory Capital Management reported no remaining Cyclerion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 376 Cyclerion Therapeutics shares in Q2 2020, an estimated $20K.
  • Victory Capital Management first reported a position in Cyclerion Therapeutics in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Cyclerion Therapeutics position peaked at $32K in Q3 2019.
  • 74 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.